Lynch syndrome is an inherited genetic condition that sharply increases your lifetime risk of developing certain cancers, especially colorectal cancer and endometrial (uterine) cancer. It affects roughly 1 in 440 people, making it the most common hereditary colorectal cancer syndrome. Many people with Lynch syndrome don’t know they carry it until a cancer diagnosis prompts genetic testing.
How Lynch Syndrome Affects DNA Repair
Your cells have a built-in proofreading system that catches and fixes errors when DNA copies itself. This system relies on a set of proteins called mismatch repair (MMR) proteins. In Lynch syndrome, one of the genes that produces these proteins carries a mutation inherited from a parent. The four genes involved are MLH1, MSH2, MSH6, and PMS2, with MLH1 and MSH2 being the most commonly affected.
Normally, when DNA copying goes wrong and nucleotides get mismatched or small sections get inserted or deleted, the MMR proteins step in and correct the mistake. With one faulty copy of an MMR gene in every cell, all it takes is for the remaining working copy to be knocked out in a single cell for the repair system to fail entirely. When that happens, errors pile up rapidly, and cells can become cancerous. This pattern of unchecked DNA errors is called microsatellite instability, and it’s one of the hallmarks doctors look for when testing a tumor for signs of Lynch syndrome.
Cancer Risks by Gene
Not all Lynch syndrome mutations carry the same level of risk. Which of the four genes is affected makes a significant difference in how likely cancer is and how early it may develop.
For colorectal cancer, the lifetime risk by age 75 breaks down roughly like this:
- MLH1: about 52% in men and 41% in women
- MSH2: about 50% in men and 39% in women
- MSH6: about 13% in men and 17% in women
- PMS2: about 11% in men and 8% in women
Compare that to the general population’s roughly 4% lifetime risk, and you can see why early, aggressive screening matters so much for people with MLH1 or MSH2 mutations in particular. Even the lower-risk MSH6 and PMS2 mutations still carry two to four times the average person’s risk.
Women with Lynch syndrome also face elevated risks for endometrial and ovarian cancers. The lifetime risk of ovarian cancer is around 8%, and endometrial cancer risk is particularly high in MLH1 and MSH2 carriers. Other cancers linked to Lynch syndrome include those of the stomach, small bowel, urinary tract (ureter and renal pelvis), pancreas, biliary tract, brain, and certain skin tumors.
How Lynch Syndrome Is Identified
Lynch syndrome is often first suspected based on a striking pattern of cancer in a family. Clinicians sometimes use what’s called the “3-2-1 rule”: at least three relatives with a Lynch-associated cancer, spanning at least two generations, with at least one case diagnosed before age 50. This framework, known as the Amsterdam II Criteria, was designed for research but became a clinical screening tool. It has limitations, though. Many families with Lynch syndrome don’t meet these strict criteria, so less rigid guidelines also exist that cast a wider net.
When a tumor is already available for testing, the most efficient first step is checking the tumor tissue itself. One common approach stains the tissue to see whether the four MMR proteins are present and functioning. If one protein is missing, it points directly to which gene is likely affected. Another approach tests the tumor DNA for microsatellite instability, the pattern of accumulated errors that signals a broken repair system. Both methods have similar accuracy in predicting who carries a germline mutation, though protein staining has the practical advantage of identifying the specific gene involved.
If tumor testing raises a red flag, the next step is a blood or saliva test to look for the inherited mutation in the suspected gene. Finding the specific mutation confirms the diagnosis and allows other family members to be tested with a simple, targeted genetic test.
Screening and Surveillance
Because colorectal cancer in Lynch syndrome can develop earlier and grow faster than typical colorectal cancers, the standard recommendation is to begin colonoscopy screening well before the age of 45 that applies to the general population. Most guidelines call for starting between ages 20 and 25, or two to five years before the youngest cancer diagnosis in the family, whichever comes first. Colonoscopies are then repeated every one to two years rather than the usual ten-year interval.
For women, European guidelines recommend endometrial cancer surveillance starting at age 35 with annual transvaginal ultrasound and periodic endometrial biopsies. These aren’t perfect screening tools, but they can catch cancers at an earlier, more treatable stage.
Reducing Cancer Risk
Daily aspirin appears to significantly lower colorectal cancer risk in people with Lynch syndrome. The landmark CAPP2 trial, which studied 861 participants taking 600 mg of aspirin daily, found a 59% reduction in colorectal cancer among those who took aspirin regularly for at least two years. Notably, the benefit didn’t appear immediately. Cancer rates between the aspirin and placebo groups started to separate only after about five years, but a relatively short treatment period (a median of roughly two and a half years) produced a long-lasting protective effect. Some medical groups now suggest a lower daily dose of 81 to 100 mg, which is easier on the stomach, though a large trial is still working to confirm the ideal dose.
For women with Lynch syndrome who have finished having children, preventive surgery is another option. Removing the uterus eliminates endometrial cancer risk entirely. For MLH1 and MSH2 carriers, removal of both ovaries and fallopian tubes at the same time is generally recommended, ideally before age 40, because the ovarian cancer risk is meaningful in these groups. For MSH6 and PMS2 carriers, ovarian removal is less clearly beneficial since their ovarian cancer risk is closer to average. That decision is typically individualized based on family history and personal preference.
Living With Lynch Syndrome
A Lynch syndrome diagnosis changes your relationship with cancer screening, but it doesn’t mean cancer is inevitable. Many carriers who follow surveillance protocols either avoid cancer entirely or catch it at an early, curable stage. The condition follows an autosomal dominant inheritance pattern, meaning each of your children has a 50% chance of inheriting the mutation. Once a specific mutation is identified in one family member, testing relatives becomes straightforward and inexpensive.
Genetic counseling is a valuable part of the process, both before and after testing. A counselor can help you interpret your specific mutation’s risk profile, coordinate screening schedules, and navigate conversations with family members about whether they want to be tested. Because the four genes carry meaningfully different risk levels, knowing your exact mutation helps tailor a surveillance plan that matches your actual risk rather than applying a one-size-fits-all approach.